Feedback Requested: Stakeholder Engagement Sessions Summary Report on Phase II of pCODR Transfer to CADTH

March 26, 2015

Hello,

In follow-up to our sessions on February 5, 2015, I am pleased to provide the report generated from stakeholder consultations on Phase II of the transfer of pCODR to CADTH.

In this report, we have summarized the key points, questions, and comments from the Stakeholder Engagement Sessions from those who participated at the sessions and to circulate this summary for those who were unable to attend. We would appreciate knowing if you feel the report accurately reflects the key issues that have been raised to date. If you have any other suggestions or thoughts about the transfer, we would be pleased to receive these as well.

In addition to general feedback on the report, we would value your input on few other questions:

1. Explore ways to further enhance transparency of the drug review process, such as, examining more open expert review committees meetings
   a. What do you understand 'open meeting' to mean?
   b. How do we do this and ensure equity? For example, it may be difficult for some groups to attend in-person.
   c. What impact on timelines would you be prepared to tolerate?

2. Explore the inclusion of individual patient/caregiver input into the health technology assessment (HTA) process
   a. From your perspective, what would be the optimal approach to obtain those perspectives when there is no patient group or related patient group representing patients for the particular disease/tumour for which a drug under review is indicated?
   b. In what ways other than through template submissions (e.g., individual interviews, focus groups), might the information from these perspectives be effectively gathered?
   c. We heard from participants that they would like to see "more voices" be represented in the HTA process. Please explain, from your perspectives, what this means to you and to outline the objectives.

3. Examining the pros and cons of mid-point review meeting (e.g., Checkpoint)
   a. What are your company's objectives for check point meetings?
   b. Are there other ways to achieve those objectives, in particular to consider the potential timing of such meetings and timelines impact on the overall process?
   c. If no, why not and if yes, what might those be?

4. Examining the pros and cons of posting initial recommendation
   a. Do you support the posting of initial recommendations?
   b. How much time is needed to respond to an initial recommendation?

c. Do you accept the likely timeline impact on the review process overall?

Please email your written feedback using our template by **May 27, 2015** at **5:00pm ET**, to **info@pcodr.ca.**

If you have any questions, please contact us at info@pcodr.ca.

We look forward to hearing from you.